Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia vi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Virol
Hlavní autoři: Kibler, Karen V., Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L., Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Roederer, Mario, Foulds, Kathryn E., Forthal, Donald N., Seaman, Michael S., Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D., Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L., Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, Jacobs, Bertram L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2019
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340019/
https://ncbi.nlm.nih.gov/pubmed/30429340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01513-18
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky